Study to Assess the Immunogenicity and Safety of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age
The purpose of this study is to evaluate the immunogenicity, safety and tolerability of
rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18
years of age.
As per the recommendation from Center for Biologics Evaluation and Research (CBER) the study
has been amended to include a new "agar-overlay" serum bactericidal assay using human serum
complement (hSBA). Additional changes include validation of the MenB manual to measure
immunogenicity of the meningococcal group B vaccine, a modification in the definition of
4-fold increase in post-vaccination hSBA titer definition when the pre-vaccination titer is
below the limit of detection, and a modification in the population set to be used for safety
analysis wherein the exposed set is to be used for all safety analyses.
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ),
Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.